The Latest Cardiac and Vascular News
Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Two Late Breaker and Six e-Poster Presentations, Including Encore of REDUCE-IT® EPA, Primary Results of the VASCEPA COVID-19 CardioLink-9 Trial, and Mechanism of Action Insights DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc […]
New ranking system introduced during first of its kind cardiovascular workforce virtual program WASHINGTON, Dec. 1, 2020 /PRNewswire/ — The Association of Black Cardiologists (ABC) announced the launch of an annual diversity and inclusion scorecard for academic cardiovascular (CV) training programs in the US. The results from this ranking initiative – ABC DIBS (Diversity, Inclusion […]
MitraClip™ Guide delivery achieved in under 7.5 minutes1 TORONTO, Dec. 1, 2020 /PRNewswire/ – A recent publication demonstrated procedural efficiency for MitraClip™ transcatheter mitral valve repair (TMVR) with use of the VersaCross® RF Transseptal Solution, reporting guide delivery from femoral access in under 7.5 minutes1. The VersaCross solution features a single radiofrequency (RF)-tipped wire used to introduce the transseptal sheath into the superior vena cava (SVC), […]
Deal Adds Innovative Solutions and Establishes High-Growth Market Leadership for Zimmer Biomet WARSAW, Ind., Dec. 1, 2020 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that the company has completed the acquisition of A&E Medical Corporation, a Vance Street Capital Portfolio Company, for $150 […]
Phase 1 results for ION449 (AZD8233) demonstrate best-in-class potential, showing potent, dose-dependent PCSK9 reductions of >90% with favorable safety profile CARLSBAD, Calif., Nov. 30, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical trial of ION449 (AZD8233), an investigational antisense medicine designed to reduce blood cholesterol levels […]
SAN CARLOS, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA] today announced that the Company’s proprietary Helix Biotherapeutic Delivery System (the Helix System) demonstrated the best safety profile among clinical transendocardial catheter injection systems used for cardiac cell therapy delivery in an in-press corrected proof published in the journal, Cardiovascular […]
Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank Meeting SOUTH SAN FRANCISCO, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq:CYTK) today announced additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 event driven cardiovascular outcomes clinical trial of omecamtiv mecarbil, will be presented at […]
TOKYO–(BUSINESS WIRE)–LUCA Science (Tokyo, Japan), a biotechnology company pioneering a novel class of mitochondrial therapeutics, announced today that it will collaborate with the Division of Cardiology, Field of Internal Medicine, Nagoya University Graduate School of Medicine to initiate a joint research on the development of mitochondrial therapy for cardiac ischemic–reperfusion […]
FLAGSTAFF, Ariz., Nov. 30, 2020 /PRNewswire/ — W. L. Gore & Associates, Inc. (Gore), a global leader in providing solutions for cardiovascular disease, today announced encouraging clinical results from its early feasibility study evaluating the safety and performance of its pulmonary valved conduit, an investigational device. Six-month data for 16 patients enrolled […]
Press release (MAR) Malmö, Sweden, November 26, 2020 FDA identifies exclusive code for the CADScor® After yesterday’s announcement and further analysis of the FDA approval, Acarix AB today announce that the company’s marketing approval of the CADScor®System in the US was granted under a new generic type of code and […]
